Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice
about
Cellular mechanisms of cardioprotection by calorie restriction: state of the science and future perspectivesLeft Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment.Interplay between oxidant species and energy metabolismGout and the risk for incident heart failure and systolic dysfunction.Cytosolic H2O2 mediates hypertrophy, apoptosis, and decreased SERCA activity in mice with chronic hemodynamic overload.Redox proteomics identification of oxidatively modified myocardial proteins in human heart failure: implications for protein function.Allopurinol benefits left ventricular mass and endothelial dysfunction in chronic kidney disease.Febuxostat pretreatment attenuates myocardial ischemia/reperfusion injury via mitochondrial apoptosis.Cardiac Biomarkers and Left Ventricular Hypertrophy in Asymptomatic Hemodialysis Patients.NADPH oxidase contributes to coronary endothelial dysfunction in the failing heartOxidative stress and cardiac hypertrophy: a review.Crucial involvement of xanthine oxidase in the intracellular signalling networks associated with human myeloid cell functionImpact of allopurinol on risk of myocardial infarction.Febuxostat improves outcome in a rat model of cancer cachexia.Delayed treatment effects of xanthine oxidase inhibition on systolic overload-induced left ventricular hypertrophy and dysfunctionChronic Kidney Disease and Disproportionally Increased Cardiovascular Damage: Does Oxidative Stress Explain the Burden?Uric Acid and New Onset Left Ventricular Hypertrophy: Findings From the PAMELA Population.Impaired cardiac mitochondrial oxidative phosphorylation and enhanced mitochondrial oxidative stress in feline hypertrophic cardiomyopathy.
P2860
Q24647295-354954D9-5FE3-4174-B95F-36E0FEB71A89Q26773120-054743E3-3F99-4C18-B3FA-E4619465816BQ28383905-52D354FB-5577-4CEB-9367-B9B78E09F08CQ30505423-F3D4033C-C768-403B-9662-A606EF8DB33CQ33626525-D939FCE7-1EF3-4DC2-9E10-B83BCAA7FEB4Q34273494-687E64D2-9A84-4130-8024-A516730BA1C5Q35108913-70707F19-E909-4D9A-90DB-FB23BDDD2AEEQ35810063-EC488940-0D06-4AAA-92A5-A69E22317F28Q36945030-9DDA4C58-7F76-4039-858D-3CC689E4F3DBQ37138926-66027F98-F4F6-4C05-820A-AC360C8EB0F5Q37991019-60ACF1D7-D458-4D0B-BB47-252ED634B914Q38958553-1CEA1745-E908-4C73-80B9-7F3702D64142Q39033643-A435785E-83FC-4BA7-B835-0F156E32C272Q41769219-FDAD0570-4C11-41BA-A14C-FA6CEFCF6972Q42107382-83AEDAF8-671C-403B-A343-BFE4114723E2Q47732797-8E818295-1EEE-460A-BA36-2FFB6CA6726DQ48640386-00F738A1-C5B0-4F56-8EAD-5779CF30FE0DQ51650069-AD05EBA5-B9D8-4AE1-B16E-2B2B8137BC6C
P2860
Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Xanthine oxidase inhibition wi ...... trophy and dysfunction in mice
@en
Xanthine oxidase inhibition wi ...... rophy and dysfunction in mice.
@nl
type
label
Xanthine oxidase inhibition wi ...... trophy and dysfunction in mice
@en
Xanthine oxidase inhibition wi ...... rophy and dysfunction in mice.
@nl
prefLabel
Xanthine oxidase inhibition wi ...... trophy and dysfunction in mice
@en
Xanthine oxidase inhibition wi ...... rophy and dysfunction in mice.
@nl
P2093
P2860
P1476
Xanthine oxidase inhibition wi ...... trophy and dysfunction in mice
@en
P2093
Jerry L Wessale
Ping Zhang
Robert J Bache
P2860
P304
P356
10.1016/J.CARDFAIL.2008.06.006
P577
2008-07-10T00:00:00Z